Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin versus placebo in children and adolescents with type 2 diabetes mellitus
MOH_2017-12-26_000698Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Alogliptin with Placebo (2 arms). Primary endpoint: Change in HbA1c. Started Dec 2017; status: active, not recruiting.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2017-12-26_000698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-26_000698.